Advertisement

The Association of Extent of Axillary Surgery and Survival in Women with N2–3 Invasive Breast Cancer

  • Tristen S. Park
  • Samantha M. Thomas
  • Laura H. Rosenberger
  • Oluwadamilola M. Fayanju
  • Jennifer K. Plichta
  • Rachel C. Blitzblau
  • Cecilia T. Ong
  • Terry Hyslop
  • E. Shelley Hwang
  • Rachel A. Greenup
Breast Oncology

Abstract

Background

Although surgical management of the axilla for breast cancer continues to evolve, axillary lymphadenectomy remains the standard of care for women with advanced nodal disease. We sought to evaluate national patterns of care in axillary surgery, and its association with overall survival (OS) among women with N2–3 invasive breast cancer.

Methods

Women (18–90 years) with clinical N2–3 invasive breast cancer who underwent axillary surgery were identified from the National Cancer Data Base (NCDB) from 2004 to 2013. Axillary surgery was categorized as sentinel lymph node biopsy (SLNB, 1–5 nodes) or axillary lymph node dissection (ALND, ≥ 10 nodes). Patient and treatment characteristics, trends over time, and overall survival (OS) were compared by surgical treatment.

Results

Overall, 22,156 patients were identified. At diagnosis, 68.5% had cN2 and 31.5% had cN3 disease. Treatment included: lumpectomy (27%), mastectomy (73%), adjuvant chemotherapy (53.4%), neoadjuvant chemotherapy (NAC) (39.7%), radiation (74%), and endocrine therapy (54.4%). In total, 9.9% (n = 2190) underwent SLNB and 90.1% (n = 19,966) underwent ALND. Receipt of SLNB was associated with private insurance, grade 3 disease, invasive ductal cancer, NAC, and lumpectomy (all p < 0.001). After adjustment for known covariates, including chemotherapy use, ALND was associated with improved survival [hazard ratio (HR) 0.68, p < 0.001] and this effect was similar for N2 and N3 patients (axillary surgery × cN-stage interaction p = 0.29).

Conclusions

Axillary lymphadenectomy was associated with improved survival in patients presenting with clinical N2–3 invasive breast cancer. Further studies, particularly in the neoadjuvant setting, are needed to identify breast cancer patients with advanced nodal disease who may safely avoid a lesser extent of axillary surgery.

References

  1. 1.
    Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63(1):181–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Fisher ER, Sass R, Fisher B. Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure. Cancer 1984;53(3 Suppl):712–23.Google Scholar
  3. 3.
    Atkinson EN, Brown BW, Montague ED. Tumor volume, nodal status, and metastasis in breast cancer in women. J Natl Cancer Inst 1986;76(2):171-8.PubMedGoogle Scholar
  4. 4.
    Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15(6):2345–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220(3):391–8 (discussion 398–401).Google Scholar
  6. 6.
    Atkins H, Hayward JL, Klugman DJ, Wayte AB. Treatment of early breast cancer: a report after ten years of a clinical trial. Br Med J 1972;2(5811):423–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hayward J, Caleffi M. The significance of local control in the primary treatment of breast cancer. Lucy Wortham James clinical research award. Arch Surg 1987;122(11):1244–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000;18(13):2553–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349(6):546–53.CrossRefPubMedGoogle Scholar
  10. 10.
    Lyman GH, Giuliano AE, Somerfield MR, Benson III AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23(30):7703–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Schwartz GF, Giuliano AE, Veronesi U, Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast April 19 to 22, 2001, Philadelphia, Pennsylvania. Hum Pathol 2002. 33(6):579–89.CrossRefPubMedGoogle Scholar
  12. 12.
    Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305(6):569–75.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252(3):426–32 (discussion 432–3).Google Scholar
  14. 14.
    Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014;15(12):1303–10.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy. Alliance 11202 Trial: NCT01872975Google Scholar
  16. 16.
  17. 17.
    Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013;14(4):297–305.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013;310(14):1455–61.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kantor O, Pesce C, Liederbach E, Wang CH, Winchester DJ, Yao K. Are the ACOSOG Z0011 trial findings being applied to breast cancer patients undergoing neoadjuvant chemotherapy? Breast J. 2017;23(5):554–62.CrossRefPubMedGoogle Scholar
  20. 20.
    Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016;34(10):1072–8.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery. NSABP B-51/RTOG 1304 Trial: NCT01872975.Google Scholar
  22. 22.
    http://www.nsabp.pitt.edu/B-51.asp. Accessed 25 June 2018.
  23. 23.
    Bonneau C, Hequet D, Estevez JP, Pouget N, Rouzier R. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes. Eur J Surg Oncol 2015;41(8):998–1004.CrossRefPubMedGoogle Scholar
  24. 24.
    Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 2010;17(Suppl 3):343–51.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009;27(18):2946–53.CrossRefPubMedGoogle Scholar
  26. 26.
    Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, De Azambuja E, Aura C, et al., Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379(9816):633–40.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol 2016;34(6):542–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24(9):2278–84.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Tristen S. Park
    • 1
  • Samantha M. Thomas
    • 2
    • 3
  • Laura H. Rosenberger
    • 3
    • 4
  • Oluwadamilola M. Fayanju
    • 3
    • 4
  • Jennifer K. Plichta
    • 3
    • 4
  • Rachel C. Blitzblau
    • 3
    • 5
  • Cecilia T. Ong
    • 4
  • Terry Hyslop
    • 2
    • 3
  • E. Shelley Hwang
    • 3
    • 4
  • Rachel A. Greenup
    • 3
    • 4
  1. 1.Department of Surgery, Yale University Medical SchoolYale Cancer Center and Smilow Cancer HospitalNew HavenUSA
  2. 2.Department of Biostatistics and BioinformaticsDuke UniversityDurhamUSA
  3. 3.Duke Cancer InstituteDuke UniversityDurhamUSA
  4. 4.Department of SurgeryDuke University Medical CenterDurhamUSA
  5. 5.Department of Radiation OncologyDuke University Medical CenterDurhamUSA

Personalised recommendations